Flow cytometric analysis of IL-17A expression in Human PBMC polarized with Th17 Polarization Kit, Human (UA090019). Th17 polarized Human PBMC were harvested and restimulated for 5 hr with PMA and Ionomycin in the presence of Brefeldin A (Right Panel) or unstimulated (Left Panel).
The cells were harvested and fixed with 4% PFA and permeabilized with Intracellular Fixation & Permeabilization Buffer Set. The cells were then stained with PE Mouse Anti-Human CD4 and SDT Alexa Fluor® 647 Human Anti-Human IL-17A Antibody at 5μl/test. Total viable cells, as determined by Fixable Viability Dye 452 (S0D0021), were used for analysis. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Alexa Fluor® 647 Human Anti-Human IL-17A Antibody (S-2815)
Alexa Fluor® 647 Human Anti-Human IL-17A Antibody (S-2815)
Price:
Regular price
$220 USD
Regular price
Sale price
$220 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | IL-17A |
| Synonyms | Interleukin-17A; IL-17; Cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8); CTLA8; IL17; IL17A |
| Location | Secreted |
| Accession | Q16552 |
| Clone Number | S-2815 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | ICFCM |
| Reactivity | Hu |
| Positive Sample | Th17 Polarization Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Alexa Fluor® 647 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ICFCM | 5μl per million cells in 100μl volume | Hu |
Background
IL-17A is a 155-amino-acid, disulfide-linked homodimeric pro-inflammatory cytokine secreted primarily by Th17 cells, γδ T cells and innate lymphoid cells; it engages the ubiquitously expressed IL-17RA/RC receptor complex to trigger TRAF6- and Act1-dependent signaling cascades that activate NF-κB, MAPKs and C/EBP transcription factors, thereby inducing massive release of neutrophil-mobilizing chemokines (CXCL1, CXCL8), G-CSF, IL-6 and antimicrobial peptides, orchestrating granulopoiesis, extracellular-matrix remodeling and barrier immunity; dysregulated IL-17A underlies autoimmune pathologies such as psoriasis, ankylosing spondylitis and multiple sclerosis, making it the target of FDA-approved biologics like secukinumab and ixekizumab.
Picture
Picture
FC
